Contrasting Aptose Biosciences (NASDAQ:APTO) & JATT Acquisition (NYSE:JATT)

JATT Acquisition (NYSE:JATT) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 26.6% of Aptose Biosciences shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by insiders. Comparatively, 1.3% of Aptose Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares JATT Acquisition and Aptose Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Aptose Biosciences	N/A	-5,683.22%	-300.44%

Analyst Recommendations

This is a breakdown of recent recommendations for JATT Acquisition and Aptose Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0	0	0	0	0.00
Aptose Biosciences	0	0	3	1	3.25

Aptose Biosciences has a consensus target price of $130.00, suggesting a potential upside of 3,712.32%. Given Aptose Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Aptose Biosciences is more favorable than JATT Acquisition.

Earnings and Valuation

This table compares JATT Acquisition and Aptose Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85 million	N/A	N/A
Aptose Biosciences	N/A	N/A	-$51.21 million	($89.19)	-0.04

Summary

JATT Acquisition beats Aptose Biosciences on 5 of the 9 factors compared between the two stocks.

About JATT Acquisition

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

About Aptose Biosciences

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.